.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
US Department of Justice
Chinese Patent Office
AstraZeneca
McKesson
McKinsey
Accenture
Baxter
Medtronic
Cerilliant

Generated: June 26, 2017

DrugPatentWatch Database Preview

Albuterol sulfate; ipratropium bromide - Generic Drug Details

« Back to Dashboard

What are the generic sources for albuterol sulfate; ipratropium bromide and what is the scope of albuterol sulfate; ipratropium bromide patent protection?

Albuterol sulfate; ipratropium bromide
is the generic ingredient in four branded drugs marketed by Apotex Inc, Teva Pharms, Boehringer Ingelheim, Nephron, Mylan Speciality Lp, Cipla Ltd, Watson Labs Teva, Sandoz Inc, and Ritedose Corp, and is included in ten NDAs. There are nineteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Albuterol sulfate; ipratropium bromide has four hundred and sixty-four patent family members in forty-four countries.

There are thirty-seven drug master file entries for albuterol sulfate; ipratropium bromide. Fourteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: albuterol sulfate; ipratropium bromide

Tradenames:4
Patents:19
Applicants:9
NDAs:10
Drug Master File Entries: see list37
Suppliers / Packagers: see list14
Clinical Trials: see list1,093
Drug Prices:see low prices
DailyMed Link:albuterol sulfate; ipratropium bromide at DailyMed

Pharmacology for Ingredient: albuterol sulfate; ipratropium bromide

Tentative approvals for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Applicant Application No. Strength Dosage Form
► Subscribe► SubscribeEQ 0.083% BASE;0.017%SOLUTION;INHALATION
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
COMBIVENT
albuterol sulfate; ipratropium bromide
AEROSOL, METERED;INHALATION020291-001Oct 24, 1996DISCNNoNo► Subscribe► Subscribe
Watson Labs Teva
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION077063-001Dec 31, 2007ANRXNoNo► Subscribe► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes6,726,124► SubscribeY ► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes6,988,496► SubscribeY ► Subscribe
Apotex Inc
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION077117-001Dec 31, 2007DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: albuterol sulfate; ipratropium bromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 20117,246,615► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 20115,662,271► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 20116,503,362► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 20115,964,416► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 20115,405,084► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: albuterol sulfate; ipratropium bromide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,084,461Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease► Subscribe
6,918,547 Device for producing high pressure in a fluid in miniature► Subscribe
7,645,383Microstructured filter► Subscribe
6,497,373 Device for producing high pressure in a fluid in miniature► Subscribe
7,451,884Container provided with a pressure equalization opening► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: albuterol sulfate; ipratropium bromide

Country Document Number Estimated Expiration
Japan4317664► Subscribe
Egypt20768► Subscribe
South Africa9610182► Subscribe
China1073472► Subscribe
Yugoslavia49228► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Cipla
Accenture
Chubb
Johnson and Johnson
Express Scripts
Novartis
Queensland Health
Baxter
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot